Profil
Gregory S.
Moss formerly worked at MeiraGTx Holdings Plc, as Director from 2018 to 2019, Kadmon Holdings, Inc., as Secretary, Chief Compliance Officer & EVP from 2019 to 2022, and MeiraGTx Ltd., as General Counsel & Compliance Officer from 2015 to 2016.
Mr. Moss received his graduate degree in 2007 from Macquarie University.
Anciens postes connus de Gregory S. Moss
| Sociétés | Poste | Fin |
|---|---|---|
| KADMON HOLDINGS, INC. | Compliance Officer | 01/06/2022 |
| MEIRAGTX HOLDINGS PLC | Directeur/Membre du Conseil | 19/06/2019 |
MeiraGTx Ltd.
 MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Compliance Officer | 01/12/2016 |
Formation de Gregory S. Moss
| Macquarie University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MEIRAGTX HOLDINGS PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
MeiraGTx Ltd.
MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Health Technology |
